Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Verweij
Jaap
J
Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands. j.verweij@erasmusmc.nl
Casali
Paolo G
PG
Zalcberg
John
J
LeCesne
Axel
A
Reichardt
Peter
P
Blay
Jean-Yves
JY
Issels
Rolf
R
van Oosterom
Allan
A
Hogendoorn
Pancras C W
PC
Van Glabbeke
Martine
M
Bertulli
Rossella
R
Judson
Ian
I
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D015996:Survival Rate
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases